Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05259566
Other study ID # 2000032211
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2022
Est. completion date March 31, 2026

Study information

Verified date January 2024
Source Yale University
Contact Krysten Bold, PhD
Phone 203-974-7603
Email Krysten.bold@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Menthol cigarette use remains a major public health problem and the FDA has proposed to ban menthol in cigarettes. However, additional evidence is needed to understand whether menthol flavor in e-cigarettes is important for harm reduction among menthol cigarette smokers in the context of a menthol cigarette ban. The primary aim of this project is to understand how the availability of menthol vs tobacco flavor e-cigarettes influences switching and reduces smoking behavior among adults who currently smoke menthol cigarettes to understand the potential effects in the context of a ban of menthol cigarettes.


Description:

Menthol cigarette use remains a major public health problem and the FDA has proposed to ban menthol in cigarettes. However, additional evidence is needed to understand whether menthol flavor in e-cigarettes is important for harm reduction among menthol cigarette smokers in the context of a menthol cigarette ban. The primary aim of this project is to understand how the availability of menthol vs tobacco flavor e-cigarettes influences switching and reduces smoking behavior among adults who currently smoke menthol cigarettes to understand the potential effects in the context of a ban of menthol cigarettes. The secondary aim of this project is to understand whether smoking behavior outcomes differ by race to understand the impact of these potential menthol ban policies on addressing tobacco-related health disparities. This single site study will take place over a 4 year study period; approximately 14 weeks for each participant's completion. 150 adults who currently smoke menthol cigarettes will be enrolled and prospectively randomized using a randomization ratio of 1:1:1 to 1 of 3 groups (N=50 per group). Following an initial baseline period where participants have access to their usual menthol cigarettes (Phase I), participants will receive tobacco products to use for 8 weeks based on their assigned group modeling 3 possible regulatory scenarios (Phase II): 1) no menthol ban (menthol cigarettes and e-cigarettes available), 2) menthol ban in cigarettes only (non-menthol cigarettes and menthol e-cigarettes available), 3) menthol ban in both cigarettes and e-cigarettes (non-menthol cigarettes and tobacco e-cigarettes available). A follow-up survey at week 12 will assess tobacco use outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date March 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Provision of signed and dated informed consent form - Age 21 or older - Able to read English - Currently smoking cigarettes - Willing to try e-cigarettes - In good general health Exclusion Criteria: - Seeking smoking cessation treatment - Serious psychiatric or medical condition - Use of other drugs - Unable or unwilling to complete study protocol - Contraindications for study procedures based on medical history

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
menthol ban in cigarettes only
menthol ban in cigarettes only, menthol available in e-cigarette
total menthol ban
menthol ban in both cigarettes and e-cigarettes

Locations

Country Name City State
United States Yale University New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Percent days of e-cigarette use Participants will report the number of days using the e-cigarette over the 8 week study period using the TLFB interview From Week 0 to week 8
Other Number of quit attempts during follow-up Number of quit attempts at the 12-week follow-up, measured by the TLFB interview methods. Week 12
Primary Average number of cigarettes smoked per day in the past week to evaluate changes in smoking behavior Participants will report the total number of cigarettes consumed each day using the well-validated timeline follow-back (TLFB) interview methods to assess change. From Week 0 to week 8
Secondary Percent days smoke-free Participants will report the number of smoke free days over the 8 week study period. Percent days smoke-free will be determined using the TLFB interview methods. From Week 0 to week 8
Secondary Changes in nicotine dependence using the Nicotine Dependence for Daily Smokers Scale Changes in nicotine dependence will be measured using the Nicotine Dependence for Daily Smokers Scale from the NIH Patient Reported Outcome Measure Information System (PROMIS) bank. Scores are averaged across 4 items, min=1, max=5. Higher scores indicate greater nicotine dependence. From Week 0 to week 8
Secondary Change in Quitting motivation and confidence Quitting motivation and confidence will be assessed using the PhenX Toolkit using the items "How motivated are you to quit smoking?" and "How confident are you that you could quit smoking if you tried?" rated from 1 (not at all) to 10 (extremely). Week 0 and week 8
Secondary Quit intentions using the Stages of Change Assessment Participants will report their plans to quit smoking in the next 30 days based on Stages of Change Assessment, on a scale from 0 (I have absolutely no intention of quitting smoking) to 10 (I have made a firm decision to quit in the next 30 days). Higher scores indicate the more intention to quit. Week 8
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Recruiting NCT04038255 - Mindfulness Based Smoking Cessation Among Cancer Survivors Phase 4
Completed NCT04123041 - Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems N/A
Completed NCT02735382 - EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study N/A
Completed NCT02139930 - Project 2: Strategies for Reducing Nicotine Content in Cigarettes N/A
Completed NCT04107779 - Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS N/A
Completed NCT05037656 - Testing a School-Based E-cigarette, Tobacco, and Betel (Areca) Nut Use Prevention Curriculum for Guam Youths N/A
Completed NCT04200157 - Testing the Decoy Effect to Increase Tobacco Treatment Uptake
Enrolling by invitation NCT06042361 - Enhancing Equity in Smoke-free Housing N/A
Completed NCT02841683 - Pragmatic Randomised Controlled Trial Evaluating Effectiveness of a Smoking Cessation e- Intervention " Tabac Info Service " N/A
Completed NCT03151421 - Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home N/A
Completed NCT04104152 - CSD190203: A Study to Determine Subject Puffing Patterns of an Electronic Nicotine Delivery System in an Ambulatory Setting N/A
Recruiting NCT05306158 - Dual Use Approach Bias Training for Nicotine Addiction N/A
Completed NCT04143256 - Evaluating Selected Constituents in the Exhaled Breath Samples N/A
Completed NCT04094363 - CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems N/A
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Completed NCT05102786 - CSD210904: Study to Assess Actual Use of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in Current Adult Smokers
Terminated NCT04396847 - Laboratory Screening of Lorcaserin for Alcohol Use Disorder Phase 2
Completed NCT03694327 - Innovative Digital Therapeutic for Smoking Cessation N/A
Completed NCT05030194 - Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study] N/A